{
  "pmcid": "12144602",
  "sha256": "44e90ca9c328dfe91436d5ff3f15be43010cc5dd6c41608b681f4105e8c65c68",
  "timestamp_utc": "2025-11-09T22:16:43.780177+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.756952264381884,
    "reading_ease": 27.78725214198289,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Uptake of Oral Tranexamic Acid During Active Labor"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this open-label, single-center pilot study, 51 women ≥36 gestational weeks with planned vaginal delivery at Södersjukhuset, Stockholm, were randomized 1:1:1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "51 women ≥36 gestational weeks with planned vaginal delivery at Södersjukhuset, Stockholm"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1:1:1 to receive 2 g of TA as an oral solution, tablets, effervescent tablets, or 1 g of intravenous TA"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to evaluate the uptake of oral TA during active labor."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were time to therapeutic level, duration in the therapeutic interval, and maximum plasma concentration."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "51 women"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Therapeutic levels were reached at 2 hours for oral (7.11 ± 3.31 mg/L) and 30 minutes for intravenous forms (30.6 ± 15.0 mg/L). Duration in therapeutic intervals was 6 hours for oral and 3.5 hours for intravenous forms (p < 0.007). Peak plasma concentrations were 10.2 ± 3.9 mg/L for oral and 30.6 ± 15.0 mg/L for intravenous forms (p < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: EudraCT-2020-002015-22"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Swedish Research Council 2019-06121"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}